Search results
Results from the WOW.Com Content Network
A MEK inhibitor is a ... approved by the FDA in June 2018 in ... Co-targeted therapeutic approaches to have been suggested to induce improved anti-cancer effects, due ...
Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [ 5 ] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K ...
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] Cobimetinib is marketed by Genentech. [2]
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [6] [7] It is a MEK inhibitor drug with anti-cancer activity. [8]
The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...
Selumetinib is a kinase inhibitor, more specifically a selective inhibitor of the enzyme mitogen-activated protein kinase kinase (MAPK kinase or MEK) subtypes 1 and 2. These enzymes are part of the MAPK/ERK pathway, which regulates cell proliferation (i.e., growth and division) and is overly active in many types of cancer. [18]
The specific compound is not approved by the FDA as a therapeutic agent, though it has been used in medical settings. [7] Members of this broad class of chemical compounds have been approved by the US FDA for the treatment of specific cancers. [8] [9] It is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase.
An existing cancer drug has shown promise in halting Parkinson's disease progression in mouse models. More research is needed to confirm these findings. Could an FDA-approved cancer drug help stop ...